Clinical Trials Browser

Lymphoma, Large B-Cell, Diffuse × parsaclisib × Clear all

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04661007 2025-12-18

J-MIND

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02998476 2025-08-22

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Phase 2 Completed

60 enrolled 15 charts

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Phase 1 Completed

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03314922 2023-08-14

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Phase 1 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03688152 2020-11-10

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse